Autopsy report · NCT00497926
Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion
Cause of deathFunding or business
“living donor kidney program terminated due to slow pace of phase 3 study enrollment”
Life of this trial
- Registered 8 months before it started.
- Ran for about 15 years 1 month before it stopped.
- 37 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Talaris Therapeutics Inc.
- Sponsor type
- Industry
- Conditions
- Kidney Failure
- Interventions
- Enriched Hematopoietic Stem Cell Infusion
- Participants
- 37
- Sites
- 2
- Countries
- United States
Trials that died the same way
- Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation
“Study terminated due to slower than anticipated enrollment.” - Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia
“Slow enrollment; study terminated.” - A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
“This study terminated prematurely because of slow enrollment” - Memantine and Antipsychotics Use
“Study terminated due to too slow enrollment” - Randomized Controlled Trial to Evaluate the Safety and Efficacy of Acetaminophen in Preterm Infants Used in Combination With Ibuprofen for Closure of the Ductus Arteriosus
“very slow enrollment. Only one patient enrolled. Termination by PI”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.